Skip to content

Computational design and evaluation of Factor Xa inhibitory peptides derived from the Tamarind Kunitz inhibitor reactive loop.

Jul 2026 · Biochemical and Biophysical Research Communications - BBRC · Vol 831, pp. 154318 · 0 citations · 31 references
Medicine

TL;DR

In-silico mutagenesis of the TKI loop (SRARISH) was performed to design improved peptide inhibitors, providing a strong computational foundation for the utilization of TKI-derived peptide inhibitors as natural anticoagulants against vascular diseases.

Abstract

Blood coagulation is a crucial process, and its dysregulation can lead to life-threatening conditions. Factor Xa (FXA) is a well-established therapeutic target for the management of vascular diseases, as it acts as a converging point of both intrinsic and extrinsic coagulation pathways. Currently available FXA inhibitors display major side effects and toxicity, necessitating novel inhibitors. We previously reported that the inhibition of FXA from the natural source by the Tamarind Kunitz Inhibitor (TKI), a Kunitz-type protease inhibitor from Tamarindus indica seeds, inhibits FXA through its seven-residue reactive loop. In this study, in-silico mutagenesis of the TKI loop (SRARISH) was performed to design improved peptide inhibitors. A peptide library was constructed and screened using molecular docking, and the top mutants were selected and subjected to MD simulations. The binding free energies calculations, principal component analysis and free energy landscape analysis were also performed to elucidate the conformational dynamics. Selected peptides showed significantly improved binding affinities over the wild-type, with total binding free energies ranging from -16.75 to -10.59 kcal/mol compared to -6.83 kcal/mol for the wild-type. The Mutant 2 (SAWWISH) emerged as the best predicted high-affinity binder with -16.75 kcal/mol binding free. The improvement results from the elimination of the electrostatic desolvation penalty and the formation of an extended aromatic scaffold that effectively interacts with the hydrophobic sub-pockets of the FXA active site. These findings provide a strong computational foundation for the utilization of TKI-derived peptide inhibitors as natural anticoagulants against vascular diseases.

View source

Similar papers

Open access Oct 2026

Design and Evaluation of Novel Peptides Targeting Protein Disulfide Isomerase as Antiplatelet Agents

Extracellular protein disulfide isomerase (PDI) is a critical mediator of thrombus formation and a promising target for novel antithrombotic therapies aiming to overcome the bleeding risks associated with current antiplatelet agents. This study aimed to design and evaluate novel, targeted peptide-based PDI inhibitors w...

Francisca Rodríguez-Cabello, Diego Méndez, Eugenia Ulzurrun et al. · 0 citations
Sep 2026

Fragment-Based AI Optimization of Tranexamic Acid Derivatives Targeting the Kringle 1 Lysine-Binding Site of Human Plasminogen: An Integrated Computational Study for Postpartum Hemorrhage

Postpartum hemorrhage remains a leading cause of maternal mortality worldwide, frequently associated with excessive fibrinolysis mediated by plasminogen activation. Tranexamic acid (TXA) is widely used as an antifibrinolytic agent; however, optimization of its scaffold may improve binding characteristics and pharmacolo...

Sinan Karageçili, Deniz Inan, Nouman Ali · 0 citations
Open access Aug 2026

Dissecting the binding landscape of four cKIT inhibitors through an integrated multifaceted approach.

This work highlights how distinct inhibitors exploit different conformational states of cKIT and demonstrates the value of integrating structural analyses, biophysical measurements, calculations and molecular simulations to define the mechanism of kinase inhibition.

Irene Cipollone, Carmen Gratteri, C. Talarico et al. · 0 citations
Open access Sep 2026

Computational Design and Evaluation of Modified AEW-1 Chalcone Derivatives as Potential Anti-Inflammatory Agents

Long-term therapy of inflammation is limited by gastrointestinal, cardiovascular, and renal side effects, motivating the search for safer, multi-target anti-inflammatory agents. The chalcone derivative AEW-1, which exhibits in vivo anti-inflammatory activity comparable to ibuprofen, was selected for rational optimizati...

Fitria Nur Hanifah, R. A. Susidarti, Niko Prasetyo · 0 citations
Open access Sep 2026

Rational discovery of peptide inhibitors targeting Keap1: a focus on neurodegenerative diseases

Introduction The Kelch-like ECH-associated protein 1 (Keap1)/Nuclear factor erythroid 2-related factor 2 (Nrf2) pathway is a promising therapeutic target for neurodegenerative diseases (NDDs). Nrf2 activation mitigates key pathogenic mechanisms in NDDs by enhancing antioxidant defenses, suppressing neuroinflammation, i...

Nandhini Senthilkumar, Shanthi Veerappapillai · 0 citations
Aug 2026

Discovery and mechanistic benchmarking of ACE inhibitory Di- and tripeptides.

Synthetic angiotensin-converting enzyme (ACE) inhibitors demonstrate clinical efficacy, but their adverse effects stimulate interest in natural, food-derived alternatives. We employed an integrated computational framework to systematically screen all possible di- and tripeptides for ACE inhibitory potential, followed b...

Yi Li, Yong-Qiang Cheng, Ning Tang · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.